Hostname: page-component-745bb68f8f-mzp66 Total loading time: 0 Render date: 2025-01-22T05:11:43.633Z Has data issue: false hasContentIssue false
  • English
  • Français

Pentamidine: A Review

Published online by Cambridge University Press:  21 March 2023

Brian Wispelwey  and
Richard D. Pearson
Brian Wispelwey*
Affiliation:
Departments of Internal Medicine and Pathology, the Divisions of Infectious Diseases and Geographic Medicine, the University of Virginia, Charlottesville, Virginia
Richard D. Pearson
Affiliation:
Departments of Internal Medicine and Pathology, the Divisions of Infectious Diseases and Geographic Medicine, the University of Virginia, Charlottesville, Virginia
*
University of Virginia, Division of Infectious Diseases, Box 397, Charlottesville, VA 22908
Get access Rights & Permissions [Opens in a new window]

Extract

With the advent of the acquired immunodeficiency syndrome (AIDS), the therapeutic importance of pentamidine isethionate has increased greatly. This review summarizes the pharmacology, clinical experience in the treatment of Pneumocystis carinii pneumonia, and toxicity of pentamidine. Data are conflicting as to whether pentamidine is more or less effective than trimethoprim-sulfamethoxazole (TMP-SX) for the treatment of P carinii pneumonia in individuals with AIDS, but due to its toxicity and expense, it is considered as second-line therapy for P carinii pneumonia by many authorities. Hypoglycemia has been encountered in up to 27%, and nephrotoxicity in 25%, of treatment courses with pentamidine. In an attempt to circumvent the toxicities associated with parenteral administration, aerosolized delivery has been evaluated for both therapy and prevention of P carinii pneumonia. Aerosolized pentamidine, on the basis of early clinical results, convenience, and low toxicity, is being used extensively to prevent P carinii pneumonia in individuals at high risk. Relapses occur, however, and pneumothorax may be more common in those using this form of prophylaxis. Aerosolized pentamidine should not be used as sole therapy for acute P carinii pneumonia.

Type
Clinical Pharmacology of Antibiotics
Information
Infection Control & Hospital Epidemiology , Volume 12 , Issue 6 , June 1991 , pp. 375 - 382
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1991

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. King, H, Lourie, EM, York, W. Studies in chemotherapy XIX: further report on new trypanocidal substances. Ann Trop Med Parasitol. 1938;32:177–192.CrossRefGoogle Scholar
2. Ivady, G, Paldy, L. Treatment of Pneumocystis carinii pneumonia in infancy. National Cancer Institute Monographs. 1976;43:201–209.Google Scholar
3. Waalkes, TP, Denham, C, De Vita, VT Pentamidine: clinical pharmacologic correlations in man and mice. Clin Pharmacol Ther. 1970;11:505–512.CrossRefGoogle ScholarPubMed
4. Conte, JE, Upton, RA, Lin, ET. Pentamidine pharmacokinetics in patients with AIDS with impaired renal function. J Infect Dis. 1987;156:885–890.CrossRefGoogle ScholarPubMed
5. Sands, M, Kron, MA, Brown, RB. Pentamidine: a review . Rev Infect Dis. 1985;7:625–634.CrossRefGoogle ScholarPubMed
6. Fitzsimmons, WE, Luskin, SS. Pentamidine therapy in renal failure: case report and literature review. Drug Intell Clin Pharm. 1988;22:25–28.Google ScholarPubMed
7. Vohringer, HF, Arasteh, K, Hardtmann, E. Distribution of pentamidine after intravenous and inhaled application in AIDS patients. 6th International Conference on AIDS; June 20-24, 1990; San Francisco, Calif: Abstract Th. B. 416.Google Scholar
8. Donnelly, H, Bernard, EM, Rothkotter, H, et al. Distribution of pentamidine in patients with AIDS. J Infect Dis. 1988;157:985–989.CrossRefGoogle ScholarPubMed
9. Wingen, F, Bragas, B. Autoradiographic examination of the organ distribution of 14C-labelled nentamidine in rats after IV and inhalative administration. 6th international Conference on AIDS; June 20-24, 1990; San Francisco, Calif: Abstract Th. B. 418.Google Scholar
10. Conte, JE, Chemoff, D, Feigal, DW, Joseph, P, McDonald, C, Golden, JA. Intravenous and inhaled nentamidine for treating Pneumocystis carinii pneumonia in AIDS. Ann Intern Med. 1990;113:203–209.CrossRefGoogle Scholar
11. Navin, TR, Diekinson, CM, Adams, SR, et al. Effect of azotemia in dogs on the pharmacokinetics of pentamidine. J Infect Dis. 1987;155:1020–1026.CrossRefGoogle ScholarPubMed
12. Sattler, FR, Cowan, R, Niielsen, DM, Ruskin, J. Trimethoprim-sulfamethoxazole compared with pentamidine for the treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med. 1988;109:280–287.CrossRefGoogle ScholarPubMed
13. Debs, RJ, Straubinger, RM, Brunette, EN, et al. Selective enhancement of pentamidine uptake in the lung by aerosolization and delivery in liposomes. Am Rev Resp Dis. 1987;135:731–737.Google Scholar
14. Monteomery, AB. Debs, RI. Luce, TM. et al. Selective delivery of pentamidine to the lung by aerosol. Am Rev Resp Dis. 1988;137:477–478.CrossRefGoogle Scholar
15. Conte, JE, Golden, JA. Concentrations of aerosolized pentamidine in bronchoalveolar lavage, systemic absorptions, and excretion. Antimicrob Agents Chemother. 1988;32:1490–1493.CrossRefGoogle Scholar
16. Williamson, J. Effects of trypanocides on the tine structure of target oreanisms. Pharmacol Ther. 1979;7:445–512.CrossRefGoogle Scholar
17. Pearson, RD, Hewlett, EL. Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoal disease. Ann Intern Med. 1985;103:782–786.CrossRefGoogle Scholar
18. Ivady, G, Paldy, L, Koltay, M, et al. Pneumocystis carinii pneumonia. Lancet. 1967;i:616–617.CrossRefGoogle Scholar
19. Walzer, PD, Perl, DP, Krogstad, DJ, et al. Pneumocystis cariniii pneumonia in the United States. Ann Intern Med. 1974;80:83–93.CrossRefGoogle Scholar
20. Hughes, WT, Feldman, S, Chaudhary, SC, et al. Comparison of pentamidine isethionate and trimethoprim-sulfmethoxazole in the treatment of Pneumocystis carinii pneumonia. J pediatr. 1978;92:285–291.CrossRefGoogle Scholar
21. Hughes, WT, Feldman, S, Sanyalsk, . Treatment of Pneumoqstis carinii pneumonia with trimethoprim-sulfamethoxazole. Can Med Assoc J. 1975;112(suppl):47–50.Google ScholarPubMed
22. Mallory, DL, Parillo, JE, Bailey, KR, et al. Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate. Crit Care Med. 1987;15:503–505.CrossRefGoogle ScholarPubMed
23. Navin, TR, Fontaine, RE. Intravenous versus intramuscular administration of pentamidine. N Engl J Med. 1984;311:1701–1702.Google ScholarPubMed
24. Small, CB. Harris, CA. Friedland, GH. Klein, RS. The treatment of Pneumocystis carinii' pneumonia in' the acquired immunodeficiency syndrome. Arch Intern Med. 1985;145:837–840.CrossRefGoogle Scholar
25. Wharton, TM. Coleman, DL. Wofsy, CB. et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med. 1986;105:37–44.CrossRefGoogle ScholarPubMed
26. Conte, JE, Hollander, H, Golden, JA. Inhaled or reduced dose intravenous pentamidine for Pneumocystis curinii pneumonia: a pilot study. Ann Intern Med. 1987;107:495–498.CrossRefGoogle ScholarPubMed
27. Montgomery, AB, Luce, JM, Turner, J, et al. Aerosolized pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Lancet. 1987;ii:480–483.CrossRefGoogle Scholar
28. Montgomery, AB, Debs, RJ, Luce, JM, et al. Aerosolized pentamidine as second-line therapy in patients with AIDS and Pneumocystis carinii pneumonia. Chest. 1989;95:747–750.CrossRefGoogle ScholarPubMed
29. Soo Hoo, GW, Mohsenifar, Z, Meyer, RD. Inhaled or intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Ann Intern Med. 1990;113:195–202.CrossRefGoogle ScholarPubMed
30. Montgomery, AB, Edison, RE, Sattler, F, et al. Aerosolized pentamidine vs. trimethoprim/sulfamethoxazole for acute Pneumocystis carinii pneumonia. 6th International Conference on AIDS; June 20-24, 1990; San Francisco, Calif: Abstract Th. B. 395.Google Scholar
31. O'Doherty, MJ, Page, C, Bradbeer, C, et al. Differences in relative efficiency of nebulizers for pentamidine administration. Lancet. 1988;ii:1283–1286.CrossRefGoogle Scholar
32. Leoung, GS, Feigal, DW, Montgomery, AB et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. N Engl J Med. 1990;323:769–775.CrossRefGoogle ScholarPubMed
33. Masur, H, Ognibene, FP, Yarchoan, R, et al. CD, counts as predictors of opportunistic pneumonias in human immunodeficiency virus infection. Ann Intern Med. 1989;114:223–231.CrossRefGoogle Scholar
34. Raviglione, MC, Currier, JS. Low-dose TMP-SX for PCP prophy1axis. AIDS Clinical Cure. 1991;3:21–22.Google Scholar
35. Golden, JA. Hollander, H. Chemoff, D. et al. Prevention of Pneumocystis carinii pneumonia by inhaled pentamidine. Luncet. 1989;i:654–657.CrossRefGoogle Scholar
36. Girard, P-M, Gaudebout, C, Lottin, P, et al. Prevention of Pneumocystis carinii pneumonia relapse by pentamidine aerosol in zidovadine-treated AIDS patients. Lancet. 1989;i:1348–1353.CrossRefGoogle Scholar
37. Abd, AG, Weitman, DM, Ilowite, JS, et al. Bilateral upper lobe Pneumocystis carinii pneumonia in a patient receiving inhaled pentamidine prophylaxis. Chest. 1988;94:329–331.CrossRefGoogle Scholar
38. Jules-Elysee, KM, Stover, DE, Zaman, MB, Bernard, EM, White, DA. Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis carinii pneumonia. Ann Intern Med. 1990;112:750–757.CrossRefGoogle ScholarPubMed
39. Baskin, MI, Abd, AG, Ilowite, JS. Regional deposition of pentamidine. Ann Intern Med. 1990;113:677–683.CrossRefGoogle ScholarPubMed
40. Sepkowitz, KA, Telzak, FE, Gold, JWM, et al. Pneumothorax in AIDS. Ann Intern Med. 1991;114:455–459.CrossRefGoogle Scholar
41. Raviglione, MC. Extrapulmonary pneumocystosis: the first 50 cases. Rev Infect Dis. 1990;12:1125–1138.CrossRefGoogle ScholarPubMed
42. Western, KA, Perera, DR, Schultz, MG. Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia. Ann Intern Med. 1970;73:695–702.CrossRefGoogle ScholarPubMed
43. Murphy, SA, Josephs, AS. Acute pancreatitis associated with pentamidine therapy. Arch Intern Med. 1981;141:56–58.CrossRefGoogle Scholar
44. Salmeron, S, Petitpretz, P, Katlama, , et al. Pentamidine and pancreatitis. Ann Intern Med. 1986;105:140–141.CrossRefGoogle ScholarPubMed
45. Zuger, A, Wolf, BZ, El Sadr, W, et al. Pentamidine-associated fatal acute pancreatitis. JAMA. 1986;256:2383–2385.CrossRefGoogle ScholarPubMed
46. Kumar, S, Schadig, VJ, MacGregor, MG. Fatal acute pancreatitis associated with pentamidine therapy. Am J Gastroenterol. 1989;84:451–453.Google ScholarPubMed
47. Stahl-Bayliss, CM, Kalman, CM, Laskin, OL. Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome. Clin Pharmacol Ther. 1986;39:271–175.CrossRefGoogle ScholarPubMed
48. Bouchard, PH, Sai, P, Reach, G, et al. Diabetes mellitus following pentamidine-induced hypoglycemia in humans. Diabetes. 1982;31:40–45.CrossRefGoogle ScholarPubMed
49. Rerup, CC. Drugs producing diabetes through damage of insulinsecreting cells. Pharmacol Rev. 1970;22:485–518.Google Scholar
50. Sai, P, Boillot, D, Boitard, C, et al. Pentamidine, a new diabetogenie drug in laboratory rodents. Diabetologia. 1983;25:418–423.CrossRefGoogle ScholarPubMed
51. Fitzgerald, DB, Young, IS. Reversal of pentamidine-induced hypoglycemia with oral diazoxide. J Trop Med Hyg. 1984;87:15–19.Google ScholarPubMed
52. Collins, RJ, Pien, FD, Houk, JH. Case report: insulin-dependent diabetes mellitus associated with pentamidine. Am J Med Sci. 1989;297:174–175.CrossRefGoogle ScholarPubMed
53. Waskin, H, Hardy, WD, McClain, N, Fall, H. Diabetes mellitus in HIV-positive patients post-pneumocystis pneumonia and the impact of aerosolized pentamidine. 6th International Conference on AIDS, June 20-24, 1990; San Francisco, Calif: Abstract Th. B. 422.Google Scholar
54. Zhou, DB, Ipp, E. Pentamidine-induced p-cell toxicity is not preventable by high glucose. Am J Med Sci. 1989;298:89–92.CrossRefGoogle Scholar
55. Lachaal, M, Venuto, RC. Nephrotoxicity and hyperkalcemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am J Med. 1989;87:260–263.CrossRefGoogle Scholar
56. Wharton, JM, Demopulos, PA, Goldschlager, N. Torsade de pointes during administration of pentamidine isethionate. Am J Med. 1987;83:571–575.CrossRefGoogle ScholarPubMed
57. Bibler, MR, Chou, T-C, Toltzis, RJ, Wade, PA. Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity. Chest. 1988;94:1306.CrossRefGoogle ScholarPubMed
58. Smith, DE, Herd, D, Guzzard, BG. Reversible bronchoconstriction with nebulized pentamidine. Lancet. 1988;ii:905.CrossRefGoogle Scholar
59. Herer, B, Chinet, T, Labrune, S, et al. Pancreatitis associated with pentamidine by aerosol. B Med J. 1989;298:605.CrossRefGoogle ScholarPubMed
60. Karboski, JA, Godley, PJ. Inhaled pentamidine and hypoglycemia. Ann Intern Med. 1988;108:490.CrossRefGoogle ScholarPubMed
61. Berger, TG, Tapper-o, JW, Leoung, GS, Jacobsen, MA. Aerosolized pentamidine and cutaneous eruptions. Ann Intern Med. 1989;110:1035–1036.CrossRefGoogle ScholarPubMed
62. Montgomery, AB, Corker-y, KJ, Brunette, ER, Leoung, GS, Waskin, H, Debs, RJ. Occupational exposure to aerosolized pentamidine. Chest. 1990;98:386–388.CrossRefGoogle ScholarPubMed
63. Centers for Disease Control. Mycobacterium tuberculosis transmission in a health clinic. Florida, 1988. MMWR. 1989;38:256–258.Google Scholar